GleamWall
中文EN

TENX TENAX THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 34956 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY0.4%
TTM EPS YoY-87.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-64.2%
ROA-59.8%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets7.1%
Debt / equity0.00x
Current ratio14.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0—
R&D expense$12.07M$12.85M$11.54M$10.54M$10.33M$6.12M$5.68M$4.59M
SG&A expense$5.66M$5.93M$5.03M$5.91M$6.48M$5.67M$5.66M$2.70M
Operating income-$17.73M-$18.78M-$16.57M-$16.45M-$16.81M-$11.79M-$11.34M-$31.69M
Interest expense———$0$0$0$0-$465
Net income-$16.70M-$17.80M-$15.72M-$15.54M-$15.80M-$10.85M-$10.41M-$28.94M
EBITDA———————-$31.69M
EPS (basic)-0.31-0.35-0.35—-0.40-0.27-0.28—
EPS (diluted)-0.31-0.35-0.35—-0.40-0.27-0.28—
Weighted avg. shares (diluted)53.45M50.87M45.23M—39.74M39.57M36.58M—
Balance sheet
Cash & equivalents$113.70M$118.00M$118.80M$97.56M$99.37M$105.46M$111.45M$94.85M
Current assets$117.01M$121.66M$123.18M$104.23M$102.81M$105.86M$112.06M$96.69M
Total assets$117.01M$121.66M$123.18M$104.23M$102.81M$105.86M$112.06M$96.69M
Current liabilities$8.36M$8.07M$8.49M$7.16M$6.60M$2.53M$2.77M$4.69M
Total liabilities$8.36M$8.07M$8.49M$7.16M$6.60M$2.53M$2.77M$4.69M
Shareholders' equity$108.66M$113.59M$114.69M$97.07M$96.21M$103.33M$109.29M$91.99M
Shares outstanding45.54M31.95M24.28M9.31M5.91M4.15M3.97M3.42M
Cash flow statement
Operating cash flow-$12.48M-$14.15M-$9.31M-$13.41M-$9.15M-$6.26M-$6.97M-$3.53M
Investing cash flow————$0$0$0$0
Financing cash flow$8.23M$13.37M$30.50M$11.61M$3.06M$278,000$23.56M$67,245
Depreciation & amortization———————$0
Stock-based compensation$2.40M$2.80M$2.84M$4.79M$5.50M$4.50M$4.14M$970,000

Free plan shows the latest 8 periods; Pro shows all 68 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.